Systemic injection of AAV9-GDNF provides modest functional improvements in the SOD1 G93A ALS rat but has adverse side effects

Gene Therapy

Volumn 24, Issue 4, 2017, Pages 245-252

  Thomsen, G M ^a   Alkaslasi, M ^a   Vit, J P ^a   Lawless, G ^a   Godoy, M ^a   Gowing, G ^a   Shelest, O ^a   Svendsen, C N ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; ADENO ASSOCIATED VIRUS VECTOR SEROTYPE 9; CHOLINE ACETYLTRANSFERASE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; UNCLASSIFIED DRUG; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SIZE; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRIP STRENGTH; HISTOPATHOLOGY; MALE; MOTOR PERFORMANCE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; RAT; SURVIVAL; SURVIVAL TIME; VIRAL GENE THERAPY; WEIGHT GAIN; WEIGHT REDUCTION; WORKING MEMORY; Y-MAZE TEST; ANIMAL; CENTRAL NERVOUS SYSTEM; DEPENDOPARVOVIRUS; DISEASE MODEL; DRUG EFFECTS; GENE THERAPY; GENE VECTOR; GENETICS; HAND STRENGTH; HUMAN; METABOLISM; MOTONEURON; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPINAL CORD; THERAPEUTIC USE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CENTRAL NERVOUS SYSTEM; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HAND STRENGTH; HUMANS; MOTOR NEURONS; RATS; SPINAL CORD; SUPEROXIDE DISMUTASE;

EID: 85014608002     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2017.9     Document Type: Article

References (52)

1. Zinman L, Cudkowicz M. Emerging targets and treatments in amyotrophic lateral sclerosis. Lancet Neurol 2011; 10: 481-490.
2. van Blitterswijk M, DeJesus-Hernandez M, Rademakers R. How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other noncoding repeat expansion disorders?. Curr Opin Neurol 2012; 25: 689-700.
3. Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis 2009; 4: 3.
4. Brenner D, Muller K, Wieland T, Weydt P, Bohm S, Lule D, et al. NEK1 mutations in familial amyotrophic lateral sclerosis. Brain 2016; 139 (Pt 5): e28.
5. Kenna KP, van Doormaal PT, Dekker AM, Ticozzi N, Kenna BJ, Diekstra FP, et al. NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nat Genet 2016; 48: 1037-1042.
6. Mueller C, Flotte TR. Clinical gene therapy using recombinant adeno-Associated virus vectors. Gene Therapy 2008; 15: 858-863.
7. Muramatsu S, Fujimoto K, Kato S, Mizukami H, Asari S, Ikeguchi K, et al A phase I study of aromatic L-Amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther 201018: 1731-1735.
8. Marks WJ Jr, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010; 9: 1164-1172.
9. LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, shamsurgery controlled, randomised trial. Lancet Neurol 2011; 10: 309-319.
10. Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 2009; 73: 1662-1669.
11. Cearley CN, Wolfe JH. Transduction characteristics of adeno-Associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther 2006; 13: 528-537.
12. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009; 27: 59-65.
13. Duque S, Joussemet B, Riviere C, Marais T, Dubreil L, Douar AM, et al. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 2009; 17: 1187-1196.
14. Foust KD, Salazar DL, Likhite S, Ferraiuolo L, Ditsworth D, Ilieva H, et al. Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol Ther 2013; 21: 2148-2159.
15. Thomsen GM GG, Latter J, Chen M, Vit JP, Staggenborg K, Avalos P, et al. Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex. J Neurosci 2014; 34: 15587-15600.
16. Stoica L, Todeasa SH, Toro Cabrera G, Salameh JS, ElMallah MK, Mueller C, et al. AAV delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model. Ann Neurol 2016; 79: 687-700.
17. Foust KD, Wang X, McGovern VL, Braun L, Bevan AK, Haidet AM, et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 2010; 28: 271-274.
18. Passini MA, Bu J, Richards AM, Treleaven CM, Sullivan JA, O'Riordan CR, et al. Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy. Hum Gene Ther 2014; 25: 619-630.
19. Meyer K, Ferraiuolo L, Schmelzer L, Braun L, McGovern V, Likhite S, et al. Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates. Mol Ther 2015; 23: 477-487.
20. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993; 260: 1130-1132.
21. Henderson CE, Phillips HS, Pollock RA, Davies AM, Lemeulle C, Armanini M, et al. GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Science 1994; 266: 1062-1064.
22. Ibanez CF, Andressoo JO. Biology of GDNF and its receptors - relevance for disorders of the central nervous system. Neurobiol Dis 2016; 97: 80-89.
23. Tovar YRLB, Ramirez-Jarquin UN, Lazo-Gomez R, Tapia R. Trophic factors as modulators of motor neuron physiology and survival: implications for ALS therapy. Front Cell Neurosci 2014; 8: 61.
24. Rakowicz WP, Staples CS, Milbrandt J, Brunstrom JE, Johnson EM Jr. Glial cell linederived neurotrophic factor promotes the survival of early postnatal spinal motor neurons in the lateral and medial motor columns in slice culture. J Neurosci 2002; 22: 3953-3962.
25. Zhang Z, Miyoshi Y, Lapchak PA, Collins F, Hilt D, Lebel C, et al. Dose response to intraventricular glial cell line-derived neurotrophic factor administration in Parkinsonian monkeys. J Pharmacol Exp Ther 1997; 282: 1396-1401.
26. Gash DM, Zhang Z, Ai Y, Grondin R, Coffey R, Gerhardt GA. Trophic factor distribution predicts functional recovery in Parkinsonian monkeys. Ann Neurol 2005; 58: 224-233.
27. Suzuki M, McHugh J, Tork C, Shelley B, Klein SM, Aebischer P, et al. GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS ONE 2007; 2: e689.
28. Suzuki M, McHugh J, Tork C, Shelley B, Hayes A, Bellantuono I, et al. Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol Ther 2008; 16: 2002-2010.
29. Nichols NL, Gowing G, Satriotomo I, Nashold LJ, Dale EA, Suzuki M, et al. Intermittent hypoxia and stem cell implants preserve breathing capacity in a rodent model of amyotrophic lateral sclerosis. Am J Respir Crit Care Med 2013; 187: 535-542.
30. Klein SM, Behrstock S, McHugh J, Hoffmann K, Wallace K, Suzuki M, et al. GDNF delivery using human neural progenitor cells in a rat model of ALS. Hum Gene Ther 2005; 16: 509-521.
31. Wang LJ, Lu YY, Muramatsu S, Ikeguchi K, Fujimoto K, Okada T, et al. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adenoassociated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J Neurosci 2002; 22: 6920-6928.
32. Lu YY, Wang LJ, Muramatsu S, Ikeguchi K, Fujimoto K, Okada T, et al. Intramuscular injection of AAV-GDNF results in sustained expression of transgenic GDNF, and its delivery to spinal motoneurons by retrograde transport. Neurosci Res 2003; 45: 33-40.
33. Acsadi G, Anguelov RA, Yang H, Toth G, Thomas R, Jani A, et al. Increased survival and function of SOD1 mice after glial cell-derived neurotrophic factor gene therapy. Hum Gene Ther 2002; 13: 1047-1059.
34. Manabe Y, Nagano I, Gazi MS, Murakami T, Shiote M, Shoji M, et al. Glial cell linederived neurotrophic factor protein prevents motor neuron loss of transgenic model mice for amyotrophic lateral sclerosis. Neurol Res 2003; 25: 195-200.
35. Xue YQ, Ma BF, Zhao LR, Tatom JB, Li B, Jiang LX, et al. AAV9-mediated erythropoietin gene delivery into the brain protects nigral dopaminergic neurons in a rat model of Parkinson's disease. Gene Therapy 2010; 17: 83-94.
36. Dufour BD, Smith CA, Clark RL, Walker TR, McBride JL. Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice. Mol Ther 2014; 22: 797-810.
37. Manfredsson FP, Tumer N, Erdos B, Landa T, Broxson CS, Sullivan LF, et al. Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity. Mol Ther 2009; 17: 980-991.
38. Kells AP, Eberling J, Su X, Pivirotto P, Bringas J, Hadaczek P, et al. Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF. J Neurosci 2010; 30: 9567-9577.
39. Su X, Kells AP, Huang EJ, Lee HS, Hadaczek P, Beyer J, et al. Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and Parkinsonian rhesus monkeys. Hum Gene Ther 2009; 20: 1627-1640.
40. Kordower JH, Palfi S, Chen EY, Ma SY, Sendera T, Cochran EJ, et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 1999; 46: 419-424.
41. Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER Jr, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003; 60: 69-73.
42. Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003; 9: 589-595.
43. Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 2005; 102: 216-222.
44. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006; 59: 459-466.
45. Li W, Brakefield D, Pan Y, Hunter D, Myckatyn TM, Parsadanian A. Muscle-derived but not centrally derived transgene GDNF is neuroprotective in G93A-SOD1 mouse model of ALS. Exp Neurol 2007; 203: 457-471.
46. Guillot S, Azzouz M, Deglon N, Zurn A, Aebischer P. Local GDNF expression mediated by lentiviral vector protects facial nerve motoneurons but not spinal motoneurons in SOD1(G93A) transgenic mice. Neurobiol Dis 2004; 16: 139-149.
47. Zhao Z, Alam S, Oppenheim RW, Prevette DM, Evenson A, Parsadanian A. Overexpression of glial cell line-derived neurotrophic factor in the CNS rescues motoneurons from programmed cell death and promotes their long-Term survival following axotomy. Exp Neurol 2004; 190: 356-372.
48. Yang C, Hutto D, Sah DW. Distribution of GDNF family receptor alpha3 and RET in rat and human non-neural tissues. J Mol Histol 2006; 37: 69-77.
49. Glerup S, Lume M, Olsen D, Nyengaard JR, Vaegter CB, Gustafsen C, et al. SorLA controls neurotrophic activity by sorting of GDNF and its receptors GFRalpha1 and RET. Cell Rep 2013; 3: 186-199.
50. Behrstock S, Ebert A, McHugh J, Vosberg S, Moore J, Schneider B, et al. Human neural progenitors deliver glial cell line-derived neurotrophic factor to Parkinsonian rodents and aged primates. Gene Therapy 2006; 13: 379-388.
51. Howland DS, Liu J, She Y, Goad B, Maragakis NJ, Kim B, et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutantmediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci USA. 2002; 99: 1604-1609.
52. Basso DM, Beattie MS, Bresnahan JC A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma 1995; 12: 1-21.